Celon Laboratories Pvt. Ltd.

Celon Laboratories is a biopharmaceutical company focused on developing and manufacturing innovative products for Oncology and Critical Care, addressing complex medical challenges through advanced therapeutic solutions. Founded in 2007 in Hyderabad, India, Celon Laboratories specializes in biopharmaceuticals. The company was acquired in November 2020 by Zanzibar Pharma Limited for INR 5. 585 billion.

Celon has successfully completed 5 funding deals, raising a total of INR 11 million. The latest funding round, an Add-on Trade Sale led by Zanzibar Pharma Limited, occurred on November 13, 2020. Celon Labs specializes in developing, manufacturing, and marketing biopharmaceutical products primarily in Oncology and Critical Care. Their offerings include Vivilon, which encompasses a broad range of oral formulations for oncology, and Revilon, targeting critical care needs.

The company employs advanced drug delivery technologies, catering to over 46 global markets, including hospitals and government institutions. In 2023, Celon Laboratories reported a revenue of INR 25,151,431 with an EBITDA of INR -6,136,031. The company operates under a B2B model, supplying products like Vivilon and Revilon directly to hospitals and healthcare institutions, facilitating bulk purchasing agreements and tailored supply contracts for effective patient treatment solutions. Celon Laboratories aims to enhance its product portfolio with upcoming launches in Oncology and Critical Care.

The recent funding from Zanzibar Pharma Limited will support these initiatives, targeting new markets in Asia by 2025. The strategic expansion will focus on increasing product accessibility in emerging healthcare sectors while improving distribution networks globally.